BLASUBCUTANEOUSSOLUTIONPriority Review
Approved
Nov 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
Priority Review
SOLIQUA 100/33 (insulin glargine and lixisenatide) by Sanofi is glucagon-like peptide-1 (glp-1) agonists [moa]. First approved in 2016.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOLIQUA 100/33 is a fixed-dose combination of insulin glargine (a long-acting basal insulin) and lixisenatide (a GLP-1 receptor agonist) administered via subcutaneous injection. It is indicated for type 2 diabetes patients requiring both basal insulin and GLP-1 agonist therapy to improve glycemic control. The combination leverages dual mechanisms: insulin's glucose-lowering effect and lixisenatide's ability to enhance insulin secretion and suppress glucagon.
Peak
Peak lifecycle indicates stable market presence with mature commercial infrastructure; teams are optimized for market defense and lifecycle management.
Mechanism of Action
Glucagon-like Peptide-1 (GLP-1) Agonists
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
Started Jan 2022
124 enrolled
Type 2 Diabetes Mellitus
Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1
Started Jun 2010
22 enrolled
Type 1 Diabetes Mellitus
Career Relevance
SOLIQUA roles span technical (data science, process engineering) and regulatory/global leadership functions, reflecting Sanofi's emphasis on digital health integration, manufacturing optimization, and regulatory compliance for a peak-lifecycle biologic. Working on SOLIQUA positions you in a mature, stable commercial franchise with strong operational and compliance visibility.
Worked on SOLIQUA 100/33 at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.